1187 related articles for article (PubMed ID: 25593112)
1. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
[TBL] [Abstract][Full Text] [Related]
2. Quantification and discriminative power of
Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
[TBL] [Abstract][Full Text] [Related]
3. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
[TBL] [Abstract][Full Text] [Related]
4. Validation of parametric methods for [¹¹C]PE2I positron emission tomography.
Jonasson M; Appel L; Engman J; Frick A; Nyholm D; Askmark H; Danfors T; Sörensen J; Furmark T; Lubberink M
Neuroimage; 2013 Jul; 74():172-8. PubMed ID: 23435214
[TBL] [Abstract][Full Text] [Related]
5. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
[TBL] [Abstract][Full Text] [Related]
6. Dopamine transporter imaging with [
Jakobson Mo S; Axelsson J; Jonasson L; Larsson A; Ögren MJ; Ögren M; Varrone A; Eriksson L; Bäckström D; Af Bjerkén S; Linder J; Riklund K
EJNMMI Res; 2018 Nov; 8(1):100. PubMed ID: 30443684
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.
Ziebell M
Dan Med Bull; 2011 May; 58(5):B4279. PubMed ID: 21535991
[TBL] [Abstract][Full Text] [Related]
8. Comparison of perfusion 18F-FP-CIT PET and 99mTc-ECD SPECT in parkinsonian disorders.
Chun K; Kong E; Cho I
Medicine (Baltimore); 2021 Aug; 100(34):e27019. PubMed ID: 34449475
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
[TBL] [Abstract][Full Text] [Related]
10. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images.
Kas A; Payoux P; Habert MO; Malek Z; Cointepas Y; El Fakhri G; Chaumet-Riffaud P; Itti E; Remy P
J Nucl Med; 2007 Sep; 48(9):1459-67. PubMed ID: 17704252
[TBL] [Abstract][Full Text] [Related]
11. Segmentation-based MR attenuation correction including bones also affects quantitation in brain studies: an initial result of 18F-FP-CIT PET/MR for patients with parkinsonism.
Choi H; Cheon GJ; Kim HJ; Choi SH; Lee JS; Kim YI; Kang KW; Chung JK; Kim EE; Lee DS
J Nucl Med; 2014 Oct; 55(10):1617-22. PubMed ID: 25134529
[TBL] [Abstract][Full Text] [Related]
12. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans.
Suzuki M; Ito H; Kodaka F; Takano H; Kimura Y; Fujiwara H; Sasaki T; Takahata K; Nogami T; Nagashima T; Nengaki N; Kawamura K; Zhang MR; Varrone A; Halldin C; Okubo Y; Suhara T
Nucl Med Commun; 2014 Mar; 35(3):231-7. PubMed ID: 24468851
[TBL] [Abstract][Full Text] [Related]
14. Improved visual [(123)I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images.
Meyer PT; Winz OH; Dafotakis M; Werner CJ; Krohn T; Schäfer WM
Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):301-9. PubMed ID: 21532542
[TBL] [Abstract][Full Text] [Related]
15. Reliability and validity of visual analysis of [ 18 F]FE-PE2I PET/CT in early Parkinsonian disease.
Af Bjerkén S; Axelsson J; Larsson A; Flygare C; Remes J; Strandberg S; Eriksson L; Bäckström D; Jakobson Mo S
Nucl Med Commun; 2023 May; 44(5):397-406. PubMed ID: 36862448
[TBL] [Abstract][Full Text] [Related]
16. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Extrastriatal
Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
[No Abstract] [Full Text] [Related]
18. Additional Role of Midbrain F-18 FP-CIT Uptake on PET in Evaluation of Essential Tremor and Parkinsonism.
Lee H; Sung YH; Hwang KH
Curr Med Imaging; 2023; 19(9):1041-1051. PubMed ID: 36734891
[TBL] [Abstract][Full Text] [Related]
19. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.
Koch W; Radau PE; Hamann C; Tatsch K
J Nucl Med; 2005 Jul; 46(7):1109-18. PubMed ID: 16000279
[TBL] [Abstract][Full Text] [Related]
20. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
